This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Contraceptive (subdermal)

Authoring team

Nexplanon® is the only contraceptive implant on the UK market. From October 2010, it replaced the bio-equivalent Implanon®. It offered an improved insertion device and added barium sulfate to enable location of lost devices on X-ray.

The single-rod contraceptive implant is 99% effective for pregnancy prevention. (2)

It works primarily by preventing ovulation and also has additional contraceptive effect by thickening the cervical mucus and thinning the endometrial lining.(3)

Reference

  1. Summary of Product Characteristics (SPC) - Nexplanon® 68 mg implant for subdermal use. Electronic Medicines Compendium, March 2019
  2. Hatcher R. Contraceptive technology. 21st ed. New York: Ardent Media; 2018.
  3. The Faculty of Sexual & Reproductive Healthcare (FSRH) of the Royal College of Obstetricians & Gynaecologists. Clinical guidance: progestogen-only implants. Feb 2021 [internet publication].

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.